NCMAG102 Abiraterone advice document: January 2023
Posted on:
Document Type
NCMAG advice
Process guidance
Summary
Adults with high-risk hormone-sensitive non-metastatic prostate cancer. (Off-label use)
Re-evaluation, supersedes NCMAG101.
Decision: supported